UK Markets open in 3 hrs 14 mins

Innate Pharma S.A. (IPHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.1000+0.0100 (+0.48%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.17
52-week change 3-64.10%
S&P500 52-week change 3-13.12%
52-week high 36.5000
52-week low 31.9200
50-day moving average 32.6175
200-day moving average 33.1771

Share statistics

Avg vol (3-month) 38.33k
Avg vol (10-day) 318.27k
Shares outstanding 579.89M
Implied shares outstanding 6N/A
Float 851.89M
% held by insiders 10.00%
% held by institutions 11.20%
Shares short (14 Sept 2022) 4111.91k
Short ratio (14 Sept 2022) 431.22
Short % of float (14 Sept 2022) 4N/A
Short % of shares outstanding (14 Sept 2022) 40.14%
Shares short (prior month 14 Aug 2022) 4109.24k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin -39.99%
Operating margin (ttm)-32.98%

Management effectiveness

Return on assets (ttm)-4.30%
Return on equity (ttm)-17.31%

Income statement

Revenue (ttm)56.98M
Revenue per share (ttm)0.71
Quarterly revenue growth (yoy)242.50%
Gross profit (ttm)-22.3M
EBITDA -14.33M
Net income avi to common (ttm)-21.63M
Diluted EPS (ttm)-0.6940
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)123.35M
Total cash per share (mrq)1.54
Total debt (mrq)43.37M
Total debt/equity (mrq)37.28
Current ratio (mrq)2.34
Book value per share (mrq)1.46

Cash flow statement

Operating cash flow (ttm)-26.08M
Levered free cash flow (ttm)-40.59M